New data highlighting the time to efficacy response observed during the 4-week treatment period from the DRM04 Phase 3 clinical program and the 12-week treatment period from the olumacostat glasaretil Phase 2b clinical trial will be presented. The data from both clinical programs will be highlighted in separate poster sessions during AAD.
“Dermira is advancing clinical programs in primary axillary hyperhidrosis and acne vulgaris, both areas of great unmet need where the standard of care hasn’t meaningfully advanced in several decades,” said
Posters of Interest:
Title: Olumacostat Glasaretil (formerly DRM01) for the Treatment of Acne Vulgaris: Primary Results from the DRM01-ACN02 Phase 2b Randomized Controlled Trial
Date and Time:
Location: Available as an ePoster in Centre 1
Abstract Number: 4835
Title: DRM04 for the Treatment of Primary Axillary Hyperhidrosis: Primary Results from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials
Date and Time:
Location: Available as an ePoster in Centre 2
Abstract Number: 4834
In addition to filings with the
DRM04 is formulated as a topical, once-daily anticholinergic agent that is currently in clinical development for the treatment of primary axillary hyperhidrosis. DRM04 is designed to block sweat production by inhibiting the interaction between acetylcholine and the cholinergic receptors responsible for sweat gland activation.
About Olumacostat Glasaretil
Olumacostat glasaretil is a novel, small molecule designed to target sebum production following topical application. Sebum is an oily substance made up of lipids produced by glands in the skin called sebaceous glands, and excessive sebum production is an important aspect of acne that is not addressed by available topical therapies. Olumacostat glasaretil is designed to exert its effect by inhibiting acetyl coenzyme-A carboxylase, an enzyme that plays an important role in the synthesis of fatty acids, a type of lipid that represents an essential component of the majority of sebum lipids.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements with respect to Dermira’s goal to build on the significant scientific advances being made in understanding skin biology to address the needs of the millions of patients living with primary axillary hyperhidrosis and acne vulgaris. These statements deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to the design, implementation and outcomes of Dermira’s clinical trials, including related to further analysis of the results of our studies; the outcome of future discussions with regulatory authorities relating to Dermira’s clinical programs; Dermira’s dependence on third-party clinical research organizations, manufacturers and suppliers; Dermira’s ability to obtain necessary additional capital; and Dermira’s ability to continue to stay in compliance with applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Dermira’s Annual Report on Form 10-K, Dermira’s Quarterly Reports on Form 10-Q and other filings Dermira makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Dermira’s forward-looking statements. Furthermore, such forward-looking statements speak only as of the date of this press release.
Erica JeffersonSenior Director, Head of Corporate Communications 650-421-7216 firstname.lastname@example.org Investors: Andrew GuggenhimeChief Operating Officer and Chief Financial Officer 650-421-7200 email@example.com Robert H. Uhl Westwicke PartnersManaging Director 858-356-5932 firstname.lastname@example.org